Brainphonics is a medtech company commercializing a scalable software platform that turns brain signals into objective, clinically actionable insights on communication and perception disorders. While many care pathways still depend on subjective behavioral tests and questionnaires, Brainphonics enables reliable objective assessments by measuring how the brain responds to everyday, real-life stimuli such as speech, social and visual cues.Our flagship product, the CORGEE software, is a medical device software solution for pediatric hearing care. Powered by patented and clinically validated EEG processing algorithms, CORGEE supports clinicians in objectively assessing speech understanding and validating hearing aid benefit, particularly in challenging populations where behavioral testing is difficult or unreliable.Brainphonics has already moved beyond the R&D and clinical trial stage: following our market launch in Q4 2025, we are generating first revenues, demonstrating early product-market traction and willingness-to-pay in research and clinical settings. With a growing base of early adopters, we are now focused on scaling commercial deployment and accelerating international expansion across Europe in 2026 and beyond.Brainphonics' technology will scale beyond a single application: it is the first commercial entry point of a broader brain-signal processing platform. The same brain technology can be extended to develop new objective biomarkers for additional populations and indications, including cognitive impairment and neuro-developmental conditions.We are raising capital to significantly commercial efforts internationally, strengthen product and regulatory development, and accelerate R&D toward new biomarkers and patient segments.